• Lunai Bioworks’ wholly owned subsidiary BioSymetrics signed a strategic collaboration LOI with BrainStorm Therapeutics to discover neurology drug targets.
• LouLou Foundation grant backs initial work in rare genetic epilepsies; broader scope includes Parkinson’s disease programs.
• BioSymetrics will pair its AI target discovery with zebrafish in vivo validation, integrated with BrainStorm’s human-derived brain organoid systems.
• Parkinson’s effort combines BrainStorm’s midbrain organoid foundation model with BioSymetrics’ analysis of the PPMI dataset to identify progression biomarkers.
• Companies aim to generate validated, partnerable neurology assets for licensing or downstream development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605280915PR_NEWS_USPR_____LA69603) on May 28, 2026, and is solely responsible for the information contained therein.